Ionis Pharmaceuticals Inc (NASDAQ: IONS) on Tuesday, plunged -1.05% from the previous trading day, before settling in for the closing price of $41.78. Within the past 52 weeks, IONS’s price has moved between $23.95 and $52.34.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
The company achieved an average annual earnings per share of -3.11%. With a float of $155.28 million, this company’s outstanding shares have now reached $159.04 million.
The firm has a total of 1069 workers. Let’s measure their productivity. In terms of profitability, gross margin is 97.75%, operating margin of -65.85%, and the pretax margin is -64.7%.
Ionis Pharmaceuticals Inc (IONS) Insider Activity
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Ionis Pharmaceuticals Inc is 2.44%, while institutional ownership is 104.18%. The most recent insider transaction that took place on May 01 ’25, was worth 477,900. In this transaction Director of this company bought 15,000 shares at a rate of $31.86, taking the stock ownership to the 50,219 shares. Before that another transaction happened on Apr 16 ’25, when Company’s EVP, Corp and Development Ops sold 680 for $28.37, making the entire transaction worth $19,292. This insider now owns 56,660 shares in total.
Ionis Pharmaceuticals Inc (IONS) Earnings and Forecasts
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.87 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -3.11% per share during the next fiscal year.
Ionis Pharmaceuticals Inc (NASDAQ: IONS) Trading Performance Indicators
Ionis Pharmaceuticals Inc (IONS) is currently performing well based on its current performance indicators. A quick ratio of 9.62 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 9.17.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.98, a number that is poised to hit -0.23 in the next quarter and is forecasted to reach -3.17 in one year’s time.
Technical Analysis of Ionis Pharmaceuticals Inc (IONS)
Analysing the last 5-days average volume posted by the [Ionis Pharmaceuticals Inc, IONS], we can find that recorded value of 2.57 million was better than the volume posted last year of 1.72 million. As of the previous 9 days, the stock’s Stochastic %D was 69.72%.
During the past 100 days, Ionis Pharmaceuticals Inc’s (IONS) raw stochastic average was set at 88.01%, which indicates a significant increase from 73.28% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 1.40 in the past 14 days, which was higher than the 1.34 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $35.23, while its 200-day Moving Average is $34.85. Now, the first resistance to watch is $41.91. This is followed by the second major resistance level at $42.47. The third major resistance level sits at $42.82. If the price goes on to break the first support level at $41.00, it is likely to go to the next support level at $40.65. Should the price break the second support level, the third support level stands at $40.09.
Ionis Pharmaceuticals Inc (NASDAQ: IONS) Key Stats
Market capitalization of the company is 6.58 billion based on 159,159K outstanding shares. Right now, sales total 705,140 K and income totals -453,900 K. The company made 131,610 K in profit during its latest quarter, and -146,940 K in sales during its previous quarter.